Developer docs
API playgroundTry for free, no card

Search company profiles

Perceptive Advisors

Full company profile

uuid00002sg

Namestring
Perceptive Advisors
Legal namestring
Perceptive Advisors, LLC
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Perceptive Advisors is a privately held investment management firm founded in 1999 by Joseph Edelman and headquartered in New York, focused exclusively on the life sciences and healthcare sectors. The firm manages approximately $8 billion in assets under management as of October 2025 with a 47-person team that includes in-house PhDs, MDs, molecular biologists, and technologists who conduct fundamental scientific due diligence on healthcare opportunities across the capital structure. Perceptive's investment approach emphasizes deep technical evaluation combined with long-term capital partnership, targeting innovation in biotechnology, drugs, medical devices, diagnostics, digital health, and life sciences research tools.

Perceptive operates four core investment strategies: the Perceptive Life Sciences Fund (a 25+ year hedge fund focused on small- to mid-cap public equities, crossover rounds, and IPO/follow-on financings), Perceptive Credit Opportunities Funds (private credit strategy launched in 2014 with approximately $3.5 billion raised, providing customized $20–$300 million debt facilities to healthcare companies), Perceptive Capital Solutions (a flexible structured-financing platform serving commercial-stage biopharma and medtech), and the Perceptive Xontogeny Venture Fund (early-stage venture capital with $700M+ in dedicated capital, leading or co-leading $10–$50 million Series A rounds). The firm additionally sponsors Perceptive Capital Solutions Corp (PCSC), a SPAC vehicle, and has expanded into direct operational ownership of healthcare platforms (Synthego, Vapotherm).

Perceptive's revenue model is based on management fees and performance-based carried interest on its closed-end funds, supplemented by interest income, warrants, and equity-linked returns from its private credit and structured financing activities. Distribution is conducted through direct institutional investment transactions, with global investment reach but no public marketing channels, consistent with a private investment firm. Investor access is restricted via password-protected portals (Northern Trust, SEI), and fund terms are negotiated privately with qualified LPs.

Short descriptiontext

Perceptive Advisors is a private investment management firm managing approximately $8 billion in life sciences-focused assets across hedge fund, private credit, structured financing, and venture capital strategies, serving healthcare companies throughout the capital structure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences investing, private credit financing, venture capital funds, structured capital solutions, healthcare investment management
Industry2 codes
PRIMARYFSANAAAL
Venture Debt Providers
SECONDARYFSANADAJ
Large-Cap / Sponsor Finance Direct Lending
Financial & Insurance/Private Equity & Venture Capital/Private Credit / Direct Lending Funds
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Investment Management
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Asset Management / Investment Management Fees
TypeManaged Services
Description

Perceptive Advisors generates revenue through management fees and performance-based carried interest on approximately $8 billion in assets under management across multiple closed-end funds (Life Sciences Fund, Credit Opportunities Funds, Xontogeny Venture Funds). Fees are earned on capital committed and deployed across public equities, private credit, venture, and structured capital solutions strategies.

perceptivelife.com
2Structured Capital Solutions Income
TypeLicensing Royalties
Description

Perceptive Capital Solutions provides structured financing to life sciences companies (e.g., $60 million credit facility to Pulmonx, $70 million credit facility to TELA Bio, $60 million to AVITA Medical), generating interest income, warrants, and equity-linked returns.

perceptivelife.com
3Private Credit Interest Income
TypeSubscription Recurring
Description

Credit Opportunities Funds deploy approximately $3.5 billion of capital into customized debt financing solutions, earning interest income (e.g., Term SOFR plus 7.0% with floor on Pulmonx facility) and warrants on minimally-dilutive loans to healthcare companies.

perceptivelife.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Investment funds with non-publicly disclosed terms
ModelOtherBilling cadenceMulti-year contract
Notes

Fund terms are negotiated privately with qualified investors; investor login portals managed via Northern Trust and SEI.

investor.omnium.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Perceptive Life Sciences Fund
Description

Flagship public-equity focused strategy making global investments in biotechnology, drugs, medical devices and diagnostics across small- to mid-cap companies.

perceptivelife.com
+3 more records
Core offering1 text field

Perceptive Advisors is a multi-strategy life sciences and healthcare investment management firm that invests across the capital structure via four closed-end fund strategies: a public-equity Life Sciences Fund, a private Credit Opportunities Fund, a Capital Solutions structured financing platform, and a Venture Capital (Xontogeny) fund for early-stage seed and Series A deals. The firm manages approximately $8 billion in assets and supports healthcare companies from discovery through commercialization, with investments sized from $10 million in venture rounds up to $300 million in credit transactions. It also sponsors a SPAC (Perceptive Capital Solutions Corp) and structures PIPEs, royalty deals and convertible financings for biopharma, medical device, diagnostics and digital health companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Flagship fund returned 75% in 2025
+5 more records
Product overview1 text field

Perceptive Advisors operates a multi-strategy platform-plus-modules architecture for life sciences investing rather than a single unified product. The core offering comprises four complementary investment strategies — the Perceptive Life Sciences Fund (PLSF) hedge fund, the Perceptive Credit Opportunities Fund for private credit, Perceptive Capital Solutions (PCS) for structured financing, and the Perceptive Xontogeny Venture Fund for early-stage venture capital — which together allow the firm to support life sciences companies across the capital structure and throughout their life cycle. On top of this, Perceptive Capital Solutions Corp (PCSC) serves as a SPAC vehicle sponsored by the firm to access public markets. These strategies collectively enable investments in public equities, private credit, structured financing, venture financings and SPAC-led public listings for biopharma, medtech, diagnostics, digital health and life sciences tools companies.

Product and service5 records
1Perceptive Life Sciences Fund (PLSF)
CategoryCore strategy / Hedge fund
Description

Long-running life sciences-focused hedge fund strategy making global investments in public and private companies developing biotechnology products, drugs, medical devices and diagnostics; invests throughout a company's life cycle including growth-stage investments, crossover rounds, IPOs and public follow-on financings, primarily in small to mid-capitalization publicly-traded companies using a fundamental scientific approach.

2Perceptive Credit Opportunities Fund
CategoryCore strategy / Private credit
Description

Private credit strategy providing customized debt financing solutions to innovative healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health and life sciences research; invests $20-$300 million per investment as minimally-dilutive growth capital.

3Perceptive Capital Solutions (PCS)
CategoryCore strategy / Structured financing
Description

Flexible capital platform providing structured financing solutions to commercial-stage and late-stage clinical biopharma and medical technology companies; delivers tailored capital that supports growth, strategic initiatives and balance sheet optimization across debt, equity-linked and structured instruments.

4Perceptive Xontogeny Venture Fund
CategoryCore strategy / Venture capital
Description

Venture capital strategy with two closed-end funds (Fund I launched 2018, Fund II closed 2021) managing over $700 million of capital dedicated to financing early-stage life sciences companies; provides lead or co-lead Series A and select growth-stage financings with investments of $10-$50 million across biotechnology, medtech, healthtech, digital health and healthcare tools/services.

5Perceptive Capital Solutions Corp (PCSC)
CategorySPAC / Public markets vehicle
Description

Special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, formed to pursue business combinations in healthcare and healthcare-related industries.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Perceptive Capital Solutions Corp (PCSC), a SPAC sponsored by Perceptive Advisors, is merging with Freenome in a $1.1B transaction with $240M PIPE (led by Perceptive Advisors and RA Capital, with Bain Capital Life Sciences and Farallon); combined entity will rename Freenome, Inc. (Nasdaq: FRNM) to commercialize blood-based cancer detection tests.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

RA Capital Management sponsors Research Alliance Corporation III (SPAC, ticker RACC) which priced a $75M IPO with Perceptive Advisors among institutional investors; close co-investment relationship across multiple transactions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large diversified asset manager with a meaningful healthcare franchise; co-investor with Perceptive on Sutro Biopharma, Solid Biosciences, Quince — broader mandate but overlapping deal participation.

TypeDirect peer
Description

Healthcare-focused hedge fund investing across public and private life sciences — overlaps with Perceptive's public-equity and PIPE activity (Adlai Nortye, Quince).

TypeDirect peer
Description

Dedicated healthcare PE/VC platform; frequently co-leads with Perceptive on AavantiBio, Imperative Care and Solid Biosciences — comparable stage range and biotech mandate.

4Baker Bros. Advisors
TypeDirect peer
Description

Long-running biotech-focused investment manager with public-equity and private financing arms; closely comparable to Perceptive Life Sciences Fund in mandate, style and scientific orientation.

TypeDirect peer
Description

Largest dedicated healthcare investment firm across public/private equity, private credit and royalties — directly comparable multi-strategy healthcare platform with comparable AUM scale.

TypeDirect peer
Description

Healthcare-focused investment firm investing across public and private life sciences with scientific orientation; recent co-investor with Perceptive on Quince Therapeutics.

TypeBroad incumbent
Description

Multi-strategy hedge fund with a significant dedicated healthcare team; co-led Opus Genetics and Quince financings with Perceptive — broader mandate but overlapping healthcare book.

TypeEmerging player
Description

Biotech-focused crossover fund led by Oleg Nodelman; comparable mandate on public/private biotech investing with somewhat smaller AUM.

TypeDirect peer
Description

Healthcare-focused crossover fund that co-leads and co-invests with Perceptive across PIPE, SPAC (RACC), and private rounds (Freenome, Capstan, Solid Biosciences, AavantiBio) — directly comparable strategy and LP base.

TypeDirect peer
Description

Healthcare-dedicated investment manager offering equity, credit and structured financing to life sciences companies — directly comparable to Perceptive's multi-strategy architecture.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment387 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Perceptive Advisors

Life Sciences Investment Managementperceptivelife.com

Perceptive Advisors is a private investment management firm managing approximately $8 billion in life sciences-focused assets across hedge fund, private credit, structured financing, and venture capital strategies, serving healthcare companies throughout the capital structure.

What Perceptive Advisors does

Perceptive Advisors is a privately held investment management firm founded in 1999 by Joseph Edelman and headquartered in New York, focused exclusively on the life sciences and healthcare sectors. The firm manages approximately $8 billion in assets under management as of October 2025 with a 47-person team that includes in-house PhDs, MDs, molecular biologists, and technologists who conduct fundamental scientific due diligence on healthcare opportunities across the capital structure. Perceptive's investment approach emphasizes deep technical evaluation combined with long-term capital partnership, targeting innovation in biotechnology, drugs, medical devices, diagnostics, digital health, and life sciences research tools.

Perceptive operates four core investment strategies: the Perceptive Life Sciences Fund (a 25+ year hedge fund focused on small- to mid-cap public equities, crossover rounds, and IPO/follow-on financings), Perceptive Credit Opportunities Funds (private credit strategy launched in 2014 with approximately $3.5 billion raised, providing customized $20–$300 million debt facilities to healthcare companies), Perceptive Capital Solutions (a flexible structured-financing platform serving commercial-stage biopharma and medtech), and the Perceptive Xontogeny Venture Fund (early-stage venture capital with $700M+ in dedicated capital, leading or co-leading $10–$50 million Series A rounds). The firm additionally sponsors Perceptive Capital Solutions Corp (PCSC), a SPAC vehicle, and has expanded into direct operational ownership of healthcare platforms (Synthego, Vapotherm).

Perceptive's revenue model is based on management fees and performance-based carried interest on its closed-end funds, supplemented by interest income, warrants, and equity-linked returns from its private credit and structured financing activities. Distribution is conducted through direct institutional investment transactions, with global investment reach but no public marketing channels, consistent with a private investment firm. Investor access is restricted via password-protected portals (Northern Trust, SEI), and fund terms are negotiated privately with qualified LPs.

Perceptive Advisors firmographics

Firmographics
Name
Perceptive Advisors
Legal name
Perceptive Advisors, LLC
Website
https://perceptivelife.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Perceptive Advisors is a private investment management firm managing approximately $8 billion in life sciences-focused assets across hedge fund, private credit, structured financing, and venture capital strategies, serving healthcare companies throughout the capital structure.
Ownership category
akta.pro rank

Perceptive Advisors industry classification

Industry
Product category
Life Sciences Investment Management
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAL
Venture Debt Providers
SECONDARYFSANADAJ
Large-Cap / Sponsor Finance Direct Lending
Financial & Insurance/Private Equity & Venture Capital/Private Credit / Direct Lending Funds

Keywords

  • Life sciences investing
  • Private credit financing
  • Venture capital funds
  • Structured capital solutions
  • Healthcare investment management

Where Perceptive Advisors is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Perceptive Advisors business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Asset Management / Investment Management Fees: Perceptive Advisors generates revenue through management fees and performance-based carried interest on approximately $8 billion in assets under management across multiple closed-end funds (Life Sciences Fund, Credit Opportunities Funds, Xontogeny Venture Funds). Fees are earned on capital committed and deployed across public equities, private credit, venture, and structured capital solutions strategies.
  2. Structured Capital Solutions Income: Perceptive Capital Solutions provides structured financing to life sciences companies (e.g., $60 million credit facility to Pulmonx, $70 million credit facility to TELA Bio, $60 million to AVITA Medical), generating interest income, warrants, and equity-linked returns.
  3. Private Credit Interest Income: Credit Opportunities Funds deploy approximately $3.5 billion of capital into customized debt financing solutions, earning interest income (e.g., Term SOFR plus 7.0% with floor on Pulmonx facility) and warrants on minimally-dilutive loans to healthcare companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInvestment funds with non-publicly disclosed terms

Go-to-market motion4 records

Distribution channels5 records

Marketing channels3 records

Perceptive Advisors product offering

Product offering

Core offering

Perceptive Advisors is a multi-strategy life sciences and healthcare investment management firm that invests across the capital structure via four closed-end fund strategies: a public-equity Life Sciences Fund, a private Credit Opportunities Fund, a Capital Solutions structured financing platform, and a Venture Capital (Xontogeny) fund for early-stage seed and Series A deals. The firm manages approximately $8 billion in assets and supports healthcare companies from discovery through commercialization, with investments sized from $10 million in venture rounds up to $300 million in credit transactions. It also sponsors a SPAC (Perceptive Capital Solutions Corp) and structures PIPEs, royalty deals and convertible financings for biopharma, medical device, diagnostics and digital health companies.

Product overview

Perceptive Advisors operates a multi-strategy platform-plus-modules architecture for life sciences investing rather than a single unified product. The core offering comprises four complementary investment strategies — the Perceptive Life Sciences Fund (PLSF) hedge fund, the Perceptive Credit Opportunities Fund for private credit, Perceptive Capital Solutions (PCS) for structured financing, and the Perceptive Xontogeny Venture Fund for early-stage venture capital — which together allow the firm to support life sciences companies across the capital structure and throughout their life cycle. On top of this, Perceptive Capital Solutions Corp (PCSC) serves as a SPAC vehicle sponsored by the firm to access public markets. These strategies collectively enable investments in public equities, private credit, structured financing, venture financings and SPAC-led public listings for biopharma, medtech, diagnostics, digital health and life sciences tools companies.

Differentiator

Problem solved

Functional benefit

Brands

  • Perceptive Life Sciences Fund: Flagship public-equity focused strategy making global investments in biotechnology, drugs, medical devices and diagnostics across small- to mid-cap companies.
  • Perceptive Credit Opportunities Funds
  • Perceptive Capital Solutions (PCS)
  • Perceptive Xontogeny Venture Fund

Products and services

  • Perceptive Life Sciences Fund (PLSF) Long-running life sciences-focused hedge fund strategy making global investments in public and private companies developing biotechnology products, drugs, medical devices and diagnostics; invests throughout a company's life cycle including growth-stage investments, crossover rounds, IPOs and public follow-on financings, primarily in small to mid-capitalization publicly-traded companies using a fundamental scientific approach.
  • Perceptive Credit Opportunities Fund Private credit strategy providing customized debt financing solutions to innovative healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health and life sciences research; invests $20-$300 million per investment as minimally-dilutive growth capital.
  • Perceptive Capital Solutions (PCS) Flexible capital platform providing structured financing solutions to commercial-stage and late-stage clinical biopharma and medical technology companies; delivers tailored capital that supports growth, strategic initiatives and balance sheet optimization across debt, equity-linked and structured instruments.
  • Perceptive Xontogeny Venture Fund Venture capital strategy with two closed-end funds (Fund I launched 2018, Fund II closed 2021) managing over $700 million of capital dedicated to financing early-stage life sciences companies; provides lead or co-lead Series A and select growth-stage financings with investments of $10-$50 million across biotechnology, medtech, healthtech, digital health and healthcare tools/services.
  • Perceptive Capital Solutions Corp (PCSC) Special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, formed to pursue business combinations in healthcare and healthcare-related industries.

Quantifiable outcome

  • Flagship fund returned 75% in 2025
  • +5 more outcomes

Companies that use Perceptive Advisors

Customer profile

Named customers1 record

Ideal customer profiles5 records

Perceptive Advisors technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Perceptive Advisors partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Freenome HoldingsflagshipStrategic or Co-development Partner · 17 June 2026Perceptive Capital Solutions Corp (PCSC), a SPAC sponsored by Perceptive Advisors, is merging with Freenome in a $1.1B transaction with $240M PIPE (led by Perceptive Advisors and RA Capital, with Bain Capital Life Sciences and Farallon); combined entity will rename Freenome, Inc. (Nasdaq: FRNM) to commercialize blood-based cancer detection tests.
  • RA Capital ManagementcoreStrategic or Co-development Partner · 20 May 2026RA Capital Management sponsors Research Alliance Corporation III (SPAC, ticker RACC) which priced a $75M IPO with Perceptive Advisors among institutional investors; close co-investment relationship across multiple transactions.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Perceptive Advisors competitors and assessment

Company assessment

Broad incumbents

  • Janus Henderson Investors: Large diversified asset manager with a meaningful healthcare franchise; co-investor with Perceptive on Sutro Biopharma, Solid Biosciences, Quince — broader mandate but overlapping deal participation.
  • Balyasny Asset Management: Multi-strategy hedge fund with a significant dedicated healthcare team; co-led Opus Genetics and Quince financings with Perceptive — broader mandate but overlapping healthcare book.

Direct peers

  • Cormorant Asset Management: Healthcare-focused hedge fund investing across public and private life sciences — overlaps with Perceptive's public-equity and PIPE activity (Adlai Nortye, Quince).
  • Bain Capital Life Sciences: Dedicated healthcare PE/VC platform; frequently co-leads with Perceptive on AavantiBio, Imperative Care and Solid Biosciences — comparable stage range and biotech mandate.
  • Baker Bros. Advisors: Long-running biotech-focused investment manager with public-equity and private financing arms; closely comparable to Perceptive Life Sciences Fund in mandate, style and scientific orientation.
  • OrbiMed Advisors: Largest dedicated healthcare investment firm across public/private equity, private credit and royalties — directly comparable multi-strategy healthcare platform with comparable AUM scale.
  • Foresite Capital: Healthcare-focused investment firm investing across public and private life sciences with scientific orientation; recent co-investor with Perceptive on Quince Therapeutics.
  • RA Capital Management: Healthcare-focused crossover fund that co-leads and co-invests with Perceptive across PIPE, SPAC (RACC), and private rounds (Freenome, Capstan, Solid Biosciences, AavantiBio) — directly comparable strategy and LP base.
  • Deerfield Management: Healthcare-dedicated investment manager offering equity, credit and structured financing to life sciences companies — directly comparable to Perceptive's multi-strategy architecture.

Emerging players

  • EcoR1 Capital: Biotech-focused crossover fund led by Oleg Nodelman; comparable mandate on public/private biotech investing with somewhat smaller AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Perceptive Advisors social profiles

Digital presence

Perceptive Advisors financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Perceptive Advisors leadership team

Management profile

Number of profiles

Profiles9 records

Perceptive Advisors subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Perceptive Advisors funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Perceptive Advisors M&A and investment

M&A and investment

M&A2 records

Investments387 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perceptive Advisors

What does Perceptive Advisors do?

Perceptive Advisors is a multi-strategy life sciences and healthcare investment management firm that invests across the capital structure via four closed-end fund strategies: a public-equity Life Sciences Fund, a private Credit Opportunities Fund, a Capital Solutions structured financing platform, and a Venture Capital (Xontogeny) fund for early-stage seed and Series A deals. The firm manages approximately $8 billion in assets and supports healthcare companies from discovery through commercialization, with investments sized from $10 million in venture rounds up to $300 million in credit transactions. It also sponsors a SPAC (Perceptive Capital Solutions Corp) and structures PIPEs, royalty deals and convertible financings for biopharma, medical device, diagnostics and digital health companies.

Is Perceptive Advisors a public or private company?

Perceptive Advisors is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Perceptive Advisors founded?

Perceptive Advisors was founded in 1999. It employs 51 to 100 people.

Where is Perceptive Advisors based?

Perceptive Advisors is headquartered in New York, United States, in the North America region.

How does Perceptive Advisors make money?

Three revenue lines are on record. Asset Management / Investment Management Fees are the primary driver. The others are structured Capital Solutions Income and private Credit Interest Income.

Who are Perceptive Advisors's main competitors?

Broad incumbents on record are Janus Henderson Investors and Balyasny Asset Management. Direct peers are Cormorant Asset Management, Bain Capital Life Sciences, Baker Bros. Advisors, OrbiMed Advisors, Foresite Capital, RA Capital Management and Deerfield Management. EcoR1 Capital is listed as an emerging player.

Does Perceptive Advisors have an API?

No public API is recorded for Perceptive Advisors.

What industry is Perceptive Advisors in?

Perceptive Advisors's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers, with a secondary code of FSANADAJ, Large-Cap / Sponsor Finance Direct Lending. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherDistalmotion Secures Up to $70 Million Venture Debt from Perceptive AdvisorsDistalmotion secured up to $70 million in venture debt from Perceptive Advisors on Oct. 21, 2026, to support its DEXTER robotic surgery system in US ambulatory surgery centers. The capital will strengthen commercial presence and advance the DEXTER platform, which is cleared for top four soft tissue procedures.Business & FinancialDistalmotion Secures Up To $70 Million Term Loan Facility From Perceptive Advisors To Accelerate US ASC ExpansionDistalmotion secured a term loan facility of up to $70 million from Perceptive Advisors to accelerate its US ambulatory surgery center expansion. The financing supports continued DEXTER robotic surgery system adoption and development. DEXTER is cleared for top four soft tissue procedures in the US.BioSpaceLisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private PlacementLisata Therapeutics acquired Marea Therapeutics and raised approximately $225 million in a private placement. The combined company will focus on Marea's MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly, with Phase 2b and Phase 2 trials expected to report topline data in Q4 2027.PR NewswireActive Wound Care Market worth $4.50 billion by 2031 - Exclusive Report by MarketsandMarkets™The active wound care market is projected to grow from $3.19 billion in 2026 to $4.50 billion by 2031, a 7.1% CAGR. North America held the largest regional share at 44.9% in 2025, and biological skin substitutes led product type with 56.8% share. Growth is driven by chronic wound prevalence and reimbursement changes, with M&A activity focusing on regenerative technologies.DocgoDocGo Signs Definitive Agreement to Acquire Virtual Care Provider Hicuity Health, Perceptive Advisors Commits to New Term Loan FundingDocGo entered a definitive agreement to acquire virtual care provider Hicuity Health, which generated about $65 million in revenue and $4.5 million adjusted EBITDA. DocGo will assume Hicuity's existing indebtedness of approximately $52 million, and Perceptive Advisors committed to up to $50 million in additional debt financing.MorningstarDocGo Announces Second Quarter 2026 ResultsDocGo reported Q2 2026 revenue of $73.4 million, down from $80.4 million, due to wind-down of migrant-related programs. Net loss was $18.0 million, and adjusted EBITDA was -$6.3 million. The company also signed a definitive agreement to acquire Hicuity Health.Business Wire BlogDocGo Announces Second Quarter 2026 ResultsDocGo Inc. announced second quarter 2026 financial results showing a net loss of $18.0 million, while reporting that core revenue excluding migrant-related programs grew 19% year over year to $73.4 million. The company simultaneously signed a definitive agreement to acquire virtual care provider Hicuity Health for approximately $52 million in assumed debt, supported by new term loan funding from Perceptive Advisors.The Manila TimesTrinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price RequirementTrinity Biotech secured an additional $7.0 million investment from Perceptive Advisors and regained compliance with Nasdaq’s minimum bid price requirement. The funding, comprising new debt and capitalized interest, strengthens the company's liquidity to support strategic initiatives including its CGM+ platform and Trinovium subsidiary. This development marks a positive step in Trinity Biotech's ongoing business transformation and operational restructuring.AInvestTrinity Biotech Surges on $7M Perceptive Lifeline as Nasdaq Risk RecedesTrinity Biotech received $7 million in support from Perceptive, easing the immediate risk of delisting from Nasdaq due to compliance with minimum bid price requirements. The funding is primarily structured as new debt with capitalized interest, offering temporary liquidity but not resolving deeper financial issues. Future success for the company depends on stabilizing its balance sheet and potentially converting debt into equity.Quiver QuantitativeTrinity Biotech Secures Additional $7 Million Investment from Perceptive Advisors and Regains Nasdaq Bid Price Compliance | TRIB Stock NewsTrinity Biotech secured an additional $7 million investment from Perceptive Advisors and regained compliance with Nasdaq's minimum bid price requirement. The funding, consisting of new debt and capitalized interest, is intended to support strategic growth initiatives including the CGM+ glucose monitoring platform and the Trinovium subsidiary. Preliminary revenues for the second quarter of 2026 were approximately $10.5 million, consistent with the previous quarter.